

WEEKLY EPIDEMIOLOGICAL REPORT

A publication of the Epidemiology Unit Ministry of Health, Nutrition & Indigenous Medicine 231, de Saram Place, Colombo 01000, Sri Lanka

Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk Web: http://www.epid.gov.lk

Zika Virus Infection

Symptoms

Vol. 43 No. 11

05th - 11th March 2016

Zika virus disease is an emerging mosquitoborne viral disease that was first identified in Uganda in 1947.

Transmission

Zika virus is a member of family Flaviviridae and it is transmitted to humans primarily by mosquitoes of Genus Aedes (*Aedes aegypti, Aedes albopictus* etc.). These are the same mosquitoes that spread dengue, chikungunya and yellow fever. Aedes mosquitoes are daytime biters who prefer to bite humans (Anthropophillic) and live both indoors and outdoors near people. It causes a mild illness known as Zika fever, Zika or Zika disease.

Incubation Period

Incubation period of Zika virus is not clear, but is likely to be few days to a week. Zika virus usually remains in blood of an infected person for few days but it can be found longer in some people.

Currently Affected Countries

Some countries of South America (Brazil, Colombia, Paraguay, Venezuela, Suriname, French Guiana, Ecuador, Guyana, Bolivia); Central America (El Salvador, Guatemala ,Mexico, Panama, Honduras); Caribbean (Martinique, Saint Martin, Puerto Rico, Haiti, Barbados, Guadeloupe) and Africa (Cape Verde) had reported local transmission of Zika virus in 2015 and 2016.

Only about 20% of people infected with Zika virus will develop the clinical disease. The most common symptoms are acute onset of fever, maculo-papular rash, arthralgia and non purulent conjunctivitis. Other common symptoms include headache, myalgia and retro-orbital pain. The symptomatic disease is generally mild and lasting for 2-7 days. Severe illness requiring hospitalization is uncommon and deaths are very rare.

Zika viral infection and pregnancy

Pregnant women can be infected with Zika virus in any trimester. There is no evidence to suggest that the pregnant women are more susceptible to Zika virus infection or experience more severe disease. Some countries have reported increase incidence of microcephaly (a condition in which a baby's head is smaller than expected when compared to babies of the same sex and age) and Guillain-Barre Syndrome during outbreaks. Health authorities are currently investigating possible potential link between Zika virus in pregnant women and microcephaly in their babies. However, more investigation and research is needed to confirm the possible association. Women who are pregnant (in any trimester) or women who planning to become pregnant are advised to consider postponing travel to any area where Zika virus transmission is ongoing. If she must travel to one of these areas, strictly follow steps to prevent mosquito bites during the trip.

Contents	Page
1. Leading Article – Zika Virus Infection	1
2. Summary of selected notifiable diseases reported $-(27^{th}-04^{th} March 2016)$	3
3. Surveillance of vaccine preventable diseases & AFP -(27 th – 04 th March 2016)	4

WER Sri Lanka - Vol. 43 No. 11

Laboratory Diagnosis and Conformation

Zika virus can be diagnosed by RT- PCR test (Real Time- Polymerase Chain Reaction) and virus isolation from blood samples. There is no widely available test to detect Zika infection. Because it is closely related to dengue and yellow fever, it may cross-react with antibody tests for those viruses. Ministry of Health has established diagnostic facilities (PCR test) for Zika virus at MRI.

Following should be considered when sending sample to MRI. 1. Request: Very brief history is mandatory highlighting followings

- Clinical features of the patient.
- Travel history within previous 2 weeks
- · Date and the day of the illness when blood was collected
- Any other investigations done to detect other viral infections such as dengue or chickungunya
- 2. Sample collection, storage and transport,
 - Sample should be collected within the first five days of illness (early sample).
 - Blood should be collected into EDTA tube or plain red top tube.
 - Minimum blood volume is 2ml.
 - Heparinized or very low volume samples (less than 2 ml) may not be accepted for testing.
 - Specimen should be transported to the laboratory at 2 to 8 °C as soon as possible.
 - In a delay is unavoidable, samples may be stored in the refrigerator at 2 to 8 ℃ up to 2 days.
 - Late samples (after day 7 of illness) may not be accepted for the zika virus PCR test.
 - Fill all the other fields in the request form very clearly and container should be properly labeled.
 - Please contact Virology department of MRI to clarify any matter in sample collection, storage and transportation.

[Source: Zika virus Real Time PCR Test (qualitative assay); Brief guideline for sent out samples; MRI]

Treatment

Page 2

Zika virus disease is usually mild and does not require any specific treatment. There is no vaccine or anti viral medication currently available to treat the Zika virus disease.

Treatment is generally supportive and based on symptomatic management;

- · Get adequate rest
- Drink adequate fluid to prevent dehydration

- Take Paracetamol to relive fever and pain
- Taking aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is not recommended.

Patients with mild illness can be managed at OPD or at home according to the decision of the physician who is attending for care of the patient and should be provide supportive symptomatic treatment and advice. Patients with severe illness should be admitted for inward care only after considering the severity of the clinical situation of individual patient.

Necessary investigations should be done to rule out the possibility of Dengue because of both conditions shares some similar clinical manifestations.

Prevention

Zika virus can be found in blood during the first week of infection. Prevention and control of disease relies on reducing mosquitoes through source reduction and avoiding contact between mosquitoes and people. All measures should be taken to keep environment clean to avoid breeding of Aedes mosquitoes.

All travellers to affected areas, showing symptoms compatible with Zika virus disease within 2 weeks of returning from an affected area should consult their medical practitioner for evaluation of the condition. Medical practitioners should inquire the travel history of the suspected cases of Zika viral disease.

People should take personal protective measures to avoid mosquito bites such as usage of mosquito repellants; wearing clothes that cover as much of the body; using physical barriers such as screens, closed doors and windows and sleeping under mosquito nets.

Pregnant women who are planning to travel to affected areas should consider postponing their visit, considering risk and benefit.

Patients should be advised to use bed nets in order to prevent the spread of disease among other patients in the wards. Hospital premises should be kept clean and fogged in regular basis (at least once in a week) where the suspected or diagnosed Zika patients being treated

Sources

1. Zika virus, available at http://www.cdc.gov/zika/

2. Zika virus, available at <u>http://www.who.int/mediacentre/</u> factsheets/zika/en/

Compiled by Dr. Alinda Perera of the Epidemiology Unit

05th - 11th March 2016

WER Sri Lanka - Vol. 43 No. 11

05th – 11th March 2016

Table 1	1: S	elec	cted	l no	tifia	able	e dis	seas	ses	rep	orte	ed b	уM	edi	cal	Offi	cer	s of	Неа	lth	27	th – ()	4 th	Mar	ch	201	6 (1	0 th	Week)
SCD	ۍ <u>*</u>	75	73	79	87	77	100	06	75	100	100	25	80	50	60	71	0	83	70	54	53	71	65	91	67	82	62	74	
Ň	*–	75	73	79	87	77	10	06	75	10	10	25	80	50	60	71	•	83	70	54	53	71	65	91	67	82	62	74	
mani-	œ	0	2	0	4	11	0	H	100	66	0	0	0	2	4	Ţ	2	1	22	0	48	34	0	7	0	0	0	305	
Leish asis	◄	0	0	0	0	0	0	0	∞	4	0	0	0	0	0	0	0	0	m	0	9	4	0	0	0	0	0	25	
ningitis	•	8	17	14	12	18	9	17	4	2	~	m		0	2	m	0	m	∞	10	10	4	23	11	30	10	ъ	258	
Mer	A	0	1	0	2	0	0			1		0	1	0	1	0	0	-	0		0	0	ß	1	0	ъ	0	22	eteness
cenpox	•	85	100	63	30	6	35	65	60	58	99	0	1	9		13	6	46	72	21	48	20	38	18	39	60	14	1007	-Comple
Chick	۲	~	8	~	ъ	-		10	~	2	13	0	0	0	0	0	0	8	2	2	ъ		2	0	m	4	ч	94	: 254 C* :
man oies	•	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			0	0	0	0		0	0	4	~	ent week
Ral	◄	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	r the curr
Viral lepatitis	•	8	12	8	21	9	m	4	10	6	4	0	0	2	0	4	m	21	∞	0	8	2	29	35	36	9	0	23	ovided fo
	◄	0	0	2	2	0	1	0	0	0	1	0	0	0	0	0	0			0	1		1	2	9	0	0	7 23	ts data pr
Typhus Fever	8	2	2	4	18	8	11	24	25	17	440	12	32	9	4	4	0	4	9	43	10	1	19	30	7	ъ	0	5 737	porting unit
<u></u>	◄	0	0	0	m	0	5		0	1	22	0	-	-	0	0	0	0	0	0	0	0		4	0	0	0	Ř	iber of re
otospiros	8	37	49	111	51	35	11	85	36	34	~	7	7	6	8	13	10	2	42	21	121	42	36	84	69	55	4	986	ts 339 Num
	A	10	6	15	0	m	0	2	4	5	0	0	0	1	0	0	0	0	ß	2	7		2	5	6	2	0	82	orting uni
Food oisoning	•	1	0	7	13	-	∞	2	34	26	14	0	1	8	4	46	0	1	2 2	0	20	ε	2	0	14	8	ъ	223	nber of rep
	4	-	0	2	2	0	0	0	0	0	н	0	0	1	0	0	0		0	0	2	0	0	0	-	-	0	12	Total nur
eric Feve	8	12	6	10	œ	4	15		0	£	26	12	8	5	10	9	0	5		m	1	8	2	2	10	11	m	175	arch, 2016
Ent	◄	-	0	1	0	0	4	0	0	2	2	0	1	0	4		0	0		0	0	-	0	1	0	0	0	19	re 04th M
cephalitis	•	0	4	ч	∞			m	0			0	4	0	0	0	0	0	4	0	н	2	9	H	10	9	ч	55	l on or befo or the year.
Ш.	◄	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	7	0		0	0	4	WRCD). receivec e cases f
/sentery	•	29	10	18	29	8	11	16	11	16	57	11	2	2	5	72	4	15	45	11	22	6	23	12	4	6	19	510	iseases (to returns Cumulative
6	4	m			2	0		0	0	-	m	0	0	0	0		0		4	0		0		m	m			3 28	cable D ss refers ek. B =
ue Fever	۵	3736	1439	659	558	86	73	441	184	245	967	29	62	92	55	190	20	167	421	361	167	111	131	91	375	357	254	11313	Communic T=Timeline: current we
Deng	۲	201	75	20	38	~	∞	8	6	14	43		m	1	12	4	0	12	23	∞	7	2	9	4	6	17	13	631	Returns of
RDHS Division		Colombo	Gampaha	Kalutara	Kandy	Matale	NuwaraEliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmune	SRILANKA	Source: Weekly A = Cases reported
																												P	age 3

WER Sri Lanka - Vol. 43 No. 11

Table 2: Vaccine-Preventable Diseases & AFP

27th - 04th March 2016 (10th Week)

05th – 11th March 2016

Disease				No. of Ca	ses by I	Province	9	Number of cases during current	Number of cases during same	Total number of cases to	Total num- ber of cases to date in	Difference between the number of cases to date			
	w	с	S	N	E	NW	NC	U	Sab	week in 2016	week in 2015	2016	2015	in 20156& 2015	
AFP*	00	00	00	00	00	00	00	02	00	02	00	13	10	+30%	
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0%	
Mumps	01	00	02	01	01	00	00	00	01	06	09	87	70	+24.2%	
Measles	01	00	00	01	00	00	00	00	00	02	29	152	273	-44.3%	
Rubella	00	00	00	00	00	00	00	00	00	00	00	05	04	+25%	
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	00	0%	
Tetanus	00	00	00	00	00	00	00	00	00	00	00	01	02	-50%	
Neonatal Teta- nus	00	00	00	00	00	00	00	00	00	00	00	00	00	0%	
Japanese En- cephalitis	00	00	00	00	00	00	00	00	00	00	00	00	03	-100%	
Whooping Cough	00	00	00	00	00	00	00	00	00	00	01	18	16	+12.5%	
Tuberculosis	54	00	07	02	04	00	00	00	00	67	251	1652	1699	-3.1%	

Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam, AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS, Special Surveillance: AFP* (Acute Flaccid Paralysis), Japanese Encephalitis

CRS** =Congenital Rubella Syndrome

AFP and all clinically confirmed Vaccine Preventable Diseases except Tuberculosis and Mumps should be investigated by the MOH

Dengue Prevention and Control Health Messages

Look for plants such as bamboo, bohemia, rampe and banana in your surroundings and maintain them

PRINTING OF THIS PUBLICATION IS FUNDED BY THE WORLD HEALTH ORGANIZATION (WHO).

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

ON STATE SERVICE

Dr. P. PALIHAWADANA CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10